Milica Gavrilović, CMP-HC

Journey to learn motivates Milica Gavrilović to seek CMP-HC certification

Upon earning her CMP in 2014, Milica says she saw an immediate impact on her skillset and ability to do her job. “It helped me speak with managers from around the world using the same language,” she said. Five years later, she knew that she wanted to continue her learning journey through the CMP-HC curriculum and certification due to the nature of her work with medical professionals.

GO LIVE TOGETHER

ABTS announces its support as a partner for Go LIVE Together, representing over 4,000 companies with U.S. operations—who have joined forces to support legislative actions that will aid the industry’s recovery from COVID-19. The coalition is bound together by the belief that nothing in the world will ever replace the power and need for trade

The International Twist

~ Davide Veglia With the COVID19 pandemic and the cancellation of many meetings and events, meeting planners are faced with the challenge of mitigating financial losses as well as maintaining brand fidelity with attendees. The entire travel service community is suffering and struggling to survive. Everyone involved: airlines, hotels, transportation, housing, exhibition, and registration companies

Why virtual events should not be replacing live experiences

In 2015 I worked on the production and organization of a series of educational events focused on hospital-acquired infections specifically for the Latin American market. We developed a whole strategy with particular attention to maximizing brand awareness and increasing revenues for the nonprofit organizer. Medical sponsors bought packages of multiple registrations and invited medical professionals

Japan becomes the first country to approve Roche’s personalized medicine Rozlytrek

Media Release Basel, 18 June 2019 First tumour-agnostic medicine approved in Japan for adult and paediatric patients with NTRK fusion-positive advanced recurrent solid tumours Approval supported by the data mainly from the pivotal Phase II STARTRK-2 study showing that Rozlytrek shrank tumours in more than half of people with NTRK fusion-positive solid tumours, across 10